News
Clairity Founder and CEO, Dr. Connie Lehman, Named to TIME’s 2026 TIME100 Health List
TIME’s Annual List Recognizes 100 of the World’s Most Influential Leaders in Health.
“Too many patients are given a cancer diagnosis when it’s too late to help them. It’s time to empower everyone, everywhere, with the information and choices we all deserve.”
Dr. Connie Lehman
Clairity’s rigorous, evidence-based approach to AI solution development is grounded in decades of breakthrough population health and radiomics research conducted by Dr. Connie Lehman at top academic medical centers including MassGeneral Brigham, MIT, and the University of Washington.
Accuracy
Improve early detection and
diagnosis
Equity
Address racial and
ethnic bias
Precision
Tailor the plan of care to each individual
Engagement
Empower patients to make informed decisions
Just like genetics, imaging data captures key insights about risk. It’s time to unlock and share those insights.
TIME’s Annual List Recognizes 100 of the World’s Most Influential Leaders in Health.
Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD, has assumed the role of Chief Executive Officer as the company enters its next phase of clinical adoption and growth. The company also announced Joe Kiani as Chairman of the Board of Directors.
Clairity, developer of the first image-only AI model authorized by the U.S. Food and Drug Administration (FDA) that estimates a woman’s five-year risk of developing breast cancer from a routine mammogram, today announced the formation of a Strategic Advisory Board to support its product path and the broad rollout and adoption of Clairity’s predictive AI technologies at scale.